Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma

[1]  M. Preusser,et al.  Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. , 2014, European journal of cancer.

[2]  Zhi Peng,et al.  Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis , 2014, PloS one.

[3]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[4]  K. O'Byrne,et al.  Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. , 2012, Clinical lung cancer.

[5]  L. Landi,et al.  Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer , 2012, British Journal of Cancer.

[6]  J. Christensen,et al.  MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells , 2012, Molecular Cancer Therapeutics.

[7]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[8]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[9]  K. Carraway,et al.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.

[10]  Jian Li,et al.  A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus , 2008, American journal of clinical oncology.

[11]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[12]  M. Campbell,et al.  Met Receptor Signaling: A Key Effector in Esophageal Adenocarcinoma , 2006, Clinical Cancer Research.

[13]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[14]  Qin Yanru.  Expression of c-myc, hTERT and c-MET in esophageal squamous cell carcinoma and lymph node metastatic tissue , 2006 .

[15]  G. Dong,et al.  Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor , 2004, Oncogene.

[16]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[17]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[18]  M. Surani,et al.  Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. , 1996, Developmental genetics.

[19]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[20]  S. Aparício,et al.  A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. , 1995, Development.

[21]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.